Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Boston Scientific to retire Lotus Edge TAVR program after voluntary recall

The company will now focus its attention on the marketing and development of other solutions.

Nurses, surgery workers had highest COVID-positive rates when the pandemic was young

Healthcare workers were infected with COVID-19 in greater percentages than the general population, and nurses were hardest hit of all, during the early days of the pandemic. 

Thumbnail

TAVR stands tall as ‘the dominant form of aortic valve replacement,’ specialty groups declare

Specialists from the American College of Cardiology and Society of Thoracic Surgeons explored data from more than 276,000 patients who have undergone a TAVR procedure in the last nine years. 

Thumbnail

Statins and side effects: What physicians, and patients, can learn from an eye-opening new study

A new placebo-controlled trial explored the various side effects patients report when on statin therapy to lower their cholesterol. 

Thumbnail

Fish oil and vitamin D supplements don’t prevent atrial fibrillation

Both supplements are still perfectly safe for patients to take for other reasons, researchers emphasized. 

Aggressive anticoagulation strategies may be harmful for COVID-19 patients

Anticoagulation therapies are an important part of treating COVID-19 patients—but there appears to be no benefit to taking a more aggressive approach.

Thumbnail

FFR measurements provide substantial value, help determine when patients need PCI

Patient outcomes are much better when clinicians use single-vessel FFR measurements to determine whether or not to perform PCI. 

New COVID concern: ‘We are asking people to take a vaccine that is going to hurt’

Will the public be braced enough for the expected side effects of shot No. 1 that they’ll follow through with the essential second round?